Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$15.23
-2.7%
$16.01
$11.44
$18.92
$5.44B0.58438,506 shs258,970 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$122.48
-3.1%
$123.04
$73.16
$148.11
$7.19B0.82885,567 shs1.54 million shs
Liquidia Corporation stock logo
LQDA
Liquidia
$65.25
+1.9%
$47.90
$11.85
$66.78
$5.80B0.581.72 million shs2.33 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$16.65
-3.4%
$14.75
$9.82
$18.92
$1.93B0.931.77 million shs982,069 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+3.26%+4.80%-3.04%-10.24%+31.21%
Glaukos Corporation stock logo
GKOS
Glaukos
+3.94%+14.03%-4.84%+23.14%+34.04%
Liquidia Corporation stock logo
LQDA
Liquidia
+0.17%+16.15%+50.98%+66.00%+255.22%
NovoCure Limited stock logo
NVCR
NovoCure
+2.31%+8.98%-3.63%+36.61%+2.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$15.23
-2.7%
$16.01
$11.44
$18.92
$5.44B0.58438,506 shs258,970 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$122.48
-3.1%
$123.04
$73.16
$148.11
$7.19B0.82885,567 shs1.54 million shs
Liquidia Corporation stock logo
LQDA
Liquidia
$65.25
+1.9%
$47.90
$11.85
$66.78
$5.80B0.581.72 million shs2.33 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$16.65
-3.4%
$14.75
$9.82
$18.92
$1.93B0.931.77 million shs982,069 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+3.26%+4.80%-3.04%-10.24%+31.21%
Glaukos Corporation stock logo
GKOS
Glaukos
+3.94%+14.03%-4.84%+23.14%+34.04%
Liquidia Corporation stock logo
LQDA
Liquidia
+0.17%+16.15%+50.98%+66.00%+255.22%
NovoCure Limited stock logo
NVCR
NovoCure
+2.31%+8.98%-3.63%+36.61%+2.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$17.9217.62% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.79
Moderate Buy$146.1719.34% Upside
Liquidia Corporation stock logo
LQDA
Liquidia
2.91
Moderate Buy$55.63-14.75% Downside
NovoCure Limited stock logo
NVCR
NovoCure
2.38
Hold$27.2963.88% Upside

Current Analyst Ratings Breakdown

Latest NVCR, GKOS, BLCO, and LQDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/10/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Reiterated RatingBuy$162.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$67.00 ➝ $75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$28.00
6/4/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Reiterated RatingStrong-Buy$68.00
6/2/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Set Price TargetBuy$19.00
6/1/2026
NovoCure Limited stock logo
NVCR
NovoCure
UpgradeSell (E+)Sell (D-)
5/26/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Reiterated RatingOutperform
5/21/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$141.00 ➝ $162.00
5/12/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$55.00 ➝ $67.00
5/12/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetOverweight$51.00 ➝ $62.00
(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.07$1.67 per share9.10$18.40 per share0.83
Glaukos Corporation stock logo
GKOS
Glaukos
$507.44M14.18N/AN/A$11.42 per share10.73
Liquidia Corporation stock logo
LQDA
Liquidia
$158.32M36.65N/AN/A$0.51 per share127.94
NovoCure Limited stock logo
NVCR
NovoCure
$655.35M2.94N/AN/A$3.04 per share5.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.62N/A14.240.47-4.21%3.60%1.69%7/29/2026 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.28N/A260.60N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)
Liquidia Corporation stock logo
LQDA
Liquidia
-$68.92M$0.14466.1013.57N/A7.74%46.82%7.06%8/11/2026 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)

Latest NVCR, GKOS, BLCO, and LQDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Liquidia Corporation stock logo
LQDA
Liquidia
$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million
4/30/2026Q1 2026
NovoCure Limited stock logo
NVCR
NovoCure
-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
4/29/2026Q1 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 million
3/18/2026Q4 2025
Liquidia Corporation stock logo
LQDA
Liquidia
$0.01$0.15+$0.14N/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Liquidia Corporation stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.43
4.73
Liquidia Corporation stock logo
LQDA
Liquidia
1.18
2.22
2.03
NovoCure Limited stock logo
NVCR
NovoCure
0.71
2.90
2.70

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Liquidia Corporation stock logo
LQDA
Liquidia
64.54%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Glaukos Corporation stock logo
GKOS
Glaukos
5.90%
Liquidia Corporation stock logo
LQDA
Liquidia
25.60%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000357.04 million351.40 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.73 million55.27 millionOptionable
Liquidia Corporation stock logo
LQDA
Liquidia
5088.93 million66.16 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,605115.82 million109.43 millionOptionable

Recent News About These Companies

NovoCure (NASDAQ:NVCR) CEO Sells $614,514.89 in Stock
Contrasting NovoCure (NASDAQ:NVCR) and HUTCHMED (NASDAQ:HCM)
NovoCure: Q1 Earnings Snapshot
NovoCure (NVCR) Q1 2026 Earnings Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$15.23 -0.42 (-2.66%)
Closing price 03:59 PM Eastern
Extended Trading
$15.26 +0.03 (+0.18%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$122.48 -3.86 (-3.05%)
Closing price 03:59 PM Eastern
Extended Trading
$122.48 +0.00 (+0.00%)
As of 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$65.25 +1.24 (+1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$65.30 +0.05 (+0.07%)
As of 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$16.65 -0.59 (-3.42%)
Closing price 04:00 PM Eastern
Extended Trading
$16.64 0.00 (-0.03%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.